195 related articles for article (PubMed ID: 36333737)
21. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Bai F; Smith MD; Chan HL; Pei XH
Oncogene; 2013 May; 32(22):2715-25. PubMed ID: 22777348
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 regulates human mammary stem/progenitor cell fate.
Liu S; Ginestier C; Charafe-Jauffret E; Foco H; Kleer CG; Merajver SD; Dontu G; Wicha MS
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1680-5. PubMed ID: 18230721
[TBL] [Abstract][Full Text] [Related]
23. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.
Jiang Z; Deng T; Jones R; Li H; Herschkowitz JI; Liu JC; Weigman VJ; Tsao MS; Lane TF; Perou CM; Zacksenhaus E
J Clin Invest; 2010 Sep; 120(9):3296-309. PubMed ID: 20679727
[TBL] [Abstract][Full Text] [Related]
24. Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
Ordonez LD; Melchor L; Greenow KR; Kendrick H; Tornillo G; Bradford J; Giles P; Smalley MJ
Dis Model Mech; 2021 May; 14(5):. PubMed ID: 34003256
[TBL] [Abstract][Full Text] [Related]
25. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12111-6. PubMed ID: 17626182
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
27. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
[TBL] [Abstract][Full Text] [Related]
28. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
[TBL] [Abstract][Full Text] [Related]
29. EZH2 Is Overexpressed in
Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
[TBL] [Abstract][Full Text] [Related]
30. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
[TBL] [Abstract][Full Text] [Related]
32. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
33. Progesterone receptor A stability is mediated by glycogen synthase kinase-3β in the Brca1-deficient mammary gland.
Wang S; Li Y; Hsu PH; Lee SY; Kim Y; Lee EYP
J Biol Chem; 2013 Sep; 288(36):26265-26274. PubMed ID: 23880761
[TBL] [Abstract][Full Text] [Related]
34. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
36. Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
McAllister KA; Wiseman RW
Breast Cancer Res; 2002; 4(2):54-7. PubMed ID: 11879563
[TBL] [Abstract][Full Text] [Related]
37. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
Scott A; Bai F; Chan HL; Liu S; Ma J; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
Oncotarget; 2016 Dec; 7(51):84496-84507. PubMed ID: 27811360
[TBL] [Abstract][Full Text] [Related]
38. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
39. A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
Hollern DP; Contreras CM; Dance-Barnes S; Silva GO; Pfefferle AD; Xiong J; Darr DB; Usary J; Mott KR; Perou CM
Breast Cancer Res Treat; 2019 Feb; 174(1):143-155. PubMed ID: 30484104
[TBL] [Abstract][Full Text] [Related]
40. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
Zhu M; Yi M; Kim CH; Deng C; Li Y; Medina D; Stephens RM; Green JE
Genome Biol; 2011 Aug; 12(8):R77. PubMed ID: 21846369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
